Gubra reports Q3 2026 earnings, advances obesity pipeline to Phase 2

Gubra A/S reported Q3 2026 financial results, with USD 50 million and EUR 10 million in partner milestones contributing to record-level earnings. Its CRO segment grew revenue 6% with a 25% EBIT margin, two partnered obesity programs advanced to Phase 2, and GUB-UCN2 entered Phase 1/2a testing.

Detected & updated continuously · Source: Nebula